FDA nominee Overton faces scrutiny over abortion drug stance

Opinion piece criticizes FDA commissioner nominee Heidi Overton for allegedly disregarding scientific evidence on mifepristone, an abortion drug. The nomination signals potential policy shift in drug regulation, but the piece is an opinion and not a factual report. The outcome of the nomination and its impact on drug approvals remain uncertain.